

Cover Story
Regulatory News
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
In Brief


Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for October 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - NCI releases names of members of ad hoc working group—filling the void left by BSA
- ACOG says it will no longer accept federal funding
- Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer
- Bhattacharya: New grant review criterion is “not political”
- Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature”